Biopsies from COVID-19 patients showed that genes associated with the NRF2-dependent antioxidant response, such as NQO1, PPAR-γ and HO-1, were decreased [27,168,169], suggesting that NRF2 activation could be a therapeutic strategy for COVID-19. The gene discussed is HMOX1; the disease is COVID-19.